Clinical Research Directory
Browse clinical research sites, groups, and studies.
Application of a Novel Biomarker Based on Plasma cfDNA Assay in the Early Diagnosis of Prostate Cancer
Sponsor: Shanghai Changzheng Hospital
Summary
The goal of this diagnostic test is to obtain multiple cell-free DNA (cfDNA) fragment profiles of subjects by whole genome sequencing based on plasma cfDNA, build a prostate cancer prediction model by machine learning, and to validate the efficacy of this model in patients who need to undergo needle prostate biopsy base on their prostate-specific antigen(PSA) or clinical or imaging evidence. Therefore, this study aims to explore the efficacy of this prostate cancer prediction model in distinguishing between patients with PSA "gray zone" (4-10 ng/ml) in the diagnosis of prostate cancer and patients with clinically significant prostate cancer.
Official title: Application of a Model Based on Plasma cfDNA Fragmentomics in the Early Diagnosis of Prostate Cancer.
Key Details
Gender
MALE
Age Range
18 Years - 80 Years
Study Type
OBSERVATIONAL
Enrollment
1100
Start Date
2024-07-09
Completion Date
2025-12
Last Updated
2024-12-27
Healthy Volunteers
No
Conditions
Interventions
Blood draw
Before undergoing a prostate biopsy, participants will have about 10 mLs of venous blood drawn. Blood will be sent to Geneseeq Technology Inc. for whole genome high-throughput sequencing of plasma cfDNA.
Locations (1)
Changzheng hospital
Shanghai, Shanghai Municipality, China